ClinicalTrials.gg
CompletedNCT01011881Updated Jun 9, 2016

Procalcitonin in Pleural Pleuritis

An observational study in Pleuritis and Pleural Empyema, sponsored by Centre Hospitalier Universitaire, Amiens. Completed at 1 site in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2016-06-09.

Sponsored by Centre Hospitalier Universitaire, Amiens · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
34
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The purpose of this study is to determine pleural level of procalcitonin in differents situations of pleuritis.

Read the detailed description

Determine pleural level of procalcitonin in pleuritis. Two periods First period evaluation in vitro study/ Determine adequat technique included type of samples tubes for adequat analysis.

Second periods : Patient with pleuritis . Empyema or not

02

Conditions studied

  • Pleuritis
  • Pleural Empyema

Keywords

  • pleuritis
  • empyema
  • procalcitonin
03

In context

Empyema, Pleural

33 studies on the registry are indexed under Empyema, Pleural; 11 are open to participants now.

Browse Empyema, Pleural studies →

Lead sponsor

Centre Hospitalier Universitaire, Amiens is the lead sponsor of 586 studies on the registry; 185 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with pleuritis

Inclusion criteria

  • Pleuritis
  • Hospitalisation

Exclusion criteria

Exclusion Criteria:

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
34 participants (actual)

Groups and cohorts

  • patients with pleuritis

    Other: pleural level of procalcitonin

Interventions

  • Otherpleural level of procalcitonin

    no intervention

06

Study locations

1 site
  • CHU Amiens
    Amiens, 80000, France
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2009
First posted
Nov 11, 2009
Start
Oct 2009
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Last update
Jun 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01011881
Responsible party
Sponsor
First posted
Nov 11, 2009
Start date
Oct 2009
Primary completion
Feb 2011
Completion
Feb 2011
Last update
Jun 9, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion